BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 37209605)

  • 1. Pedunculoside inhibits epithelial-mesenchymal transition and overcomes Gefitinib-resistant non-small cell lung cancer through regulating MAPK and Nrf2 pathways.
    Fan Q; Liang X; Xu Z; Li S; Han S; Xiao Y; Xu Q; Yuan R; Yang S; Gao H
    Phytomedicine; 2023 Jul; 116():154884. PubMed ID: 37209605
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cucurbitacin B inhibits TGF-β1-induced epithelial-mesenchymal transition (EMT) in NSCLC through regulating ROS and PI3K/Akt/mTOR pathways.
    Yuan R; Fan Q; Liang X; Han S; He J; Wang QQ; Gao H; Feng Y; Yang S
    Chin Med; 2022 Feb; 17(1):24. PubMed ID: 35183200
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MiR-134/487b/655 cluster regulates TGF-β-induced epithelial-mesenchymal transition and drug resistance to gefitinib by targeting MAGI2 in lung adenocarcinoma cells.
    Kitamura K; Seike M; Okano T; Matsuda K; Miyanaga A; Mizutani H; Noro R; Minegishi Y; Kubota K; Gemma A
    Mol Cancer Ther; 2014 Feb; 13(2):444-53. PubMed ID: 24258346
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fucoxanthin extracted from Laminaria Japonica inhibits metastasis and enhances the sensitivity of lung cancer to Gefitinib.
    Ming JX; Wang ZC; Huang Y; Ohishi H; Wu RJ; Shao Y; Wang H; Qin MY; Wu ZL; Li YY; Chang Zhou S; Chen H; Liu H; Xu R
    J Ethnopharmacol; 2021 Jan; 265():113302. PubMed ID: 32860893
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Delivery of gefitinib in synergism with thymoquinone
    Upadhyay P; Ghosh A; Basu A; Pranati PA; Gupta P; Das S; Sarker S; Bhattacharjee M; Bhattacharya S; Ghosh S; Chattopadhyay S; Adhikary A
    Biomater Sci; 2021 Dec; 9(24):8285-8312. PubMed ID: 34766965
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epithelial to mesenchymal transition derived from repeated exposure to gefitinib determines the sensitivity to EGFR inhibitors in A549, a non-small cell lung cancer cell line.
    Rho JK; Choi YJ; Lee JK; Ryoo BY; Na II; Yang SH; Kim CH; Lee JC
    Lung Cancer; 2009 Feb; 63(2):219-26. PubMed ID: 18599154
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cucurbitacin B Induces the Lysosomal Degradation of EGFR and Suppresses the CIP2A/PP2A/Akt Signaling Axis in Gefitinib-Resistant Non-Small Cell Lung Cancer.
    Liu P; Xiang Y; Liu X; Zhang T; Yang R; Chen S; Xu L; Yu Q; Zhao H; Zhang L; Liu Y; Si Y
    Molecules; 2019 Feb; 24(3):. PubMed ID: 30759826
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug-resistant CXCR4-positive cells have the molecular characteristics of EMT in NSCLC.
    Yin H; Wang Y; Chen W; Zhong S; Liu Z; Zhao J
    Gene; 2016 Dec; 594(1):23-29. PubMed ID: 27581786
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FGL1 regulates acquired resistance to Gefitinib by inhibiting apoptosis in non-small cell lung cancer.
    Sun C; Gao W; Liu J; Cheng H; Hao J
    Respir Res; 2020 Aug; 21(1):210. PubMed ID: 32778129
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EZH2 inhibitors reverse resistance to gefitinib in primary EGFR wild-type lung cancer cells.
    Gong H; Li Y; Yuan Y; Li W; Zhang H; Zhang Z; Shi R; Liu M; Liu C; Chen C; Liu H; Chen J
    BMC Cancer; 2020 Dec; 20(1):1189. PubMed ID: 33276757
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined treatment with N-acetylcysteine and gefitinib overcomes drug resistance to gefitinib in NSCLC cell line.
    Li J; Wang XH; Hu J; Shi M; Zhang L; Chen H
    Cancer Med; 2020 Feb; 9(4):1495-1502. PubMed ID: 31891230
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gefitinib promotes CXCR4-dependent epithelial to mesenchymal transition via TGF-β1 signaling pathway in lung cancer cells harboring EGFR mutation.
    Zhu Q; Zhang Z; Lu C; Xu F; Mao W; Zhang K; Shou H; Liu Z; Gu J; Ge D
    Clin Transl Oncol; 2020 Aug; 22(8):1355-1363. PubMed ID: 31900845
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epigenetic silencing of miR-483-3p promotes acquired gefitinib resistance and EMT in EGFR-mutant NSCLC by targeting integrin β3.
    Yue J; Lv D; Wang C; Li L; Zhao Q; Chen H; Xu L
    Oncogene; 2018 Aug; 37(31):4300-4312. PubMed ID: 29717264
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SOX9 promotes epidermal growth factor receptor-tyrosine kinase inhibitor resistance via targeting β-catenin and epithelial to mesenchymal transition in lung cancer.
    Tripathi SK; Biswal BK
    Life Sci; 2021 Jul; 277():119608. PubMed ID: 33989664
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chinese medicine Bu-Fei decoction attenuates epithelial-mesenchymal transition of non-small cell lung cancer via inhibition of transforming growth factor β1 signaling pathway in vitro and in vivo.
    He XR; Han SY; Li XH; Zheng WX; Pang LN; Jiang ST; Li PP
    J Ethnopharmacol; 2017 May; 204():45-57. PubMed ID: 28412214
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stereospecific effects of ginsenoside 20-Rg3 inhibits TGF-β1-induced epithelial-mesenchymal transition and suppresses lung cancer migration, invasion and anoikis resistance.
    Kim YJ; Choi WI; Jeon BN; Choi KC; Kim K; Kim TJ; Ham J; Jang HJ; Kang KS; Ko H
    Toxicology; 2014 Aug; 322():23-33. PubMed ID: 24793912
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nagilactone E suppresses TGF-β1-induced epithelial-mesenchymal transition, migration and invasion in non-small cell lung cancer cells.
    Zhang LL; Jiang XM; Huang MY; Feng ZL; Chen X; Wang Y; Li H; Li A; Lin LG; Lu JJ
    Phytomedicine; 2019 Jan; 52():32-39. PubMed ID: 30599910
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interaction of hnRNP K with MAP 1B-LC1 promotes TGF-β1-mediated epithelial to mesenchymal transition in lung cancer cells.
    Li L; Yan S; Zhang H; Zhang M; Huang G; Chen M
    BMC Cancer; 2019 Sep; 19(1):894. PubMed ID: 31492158
    [TBL] [Abstract][Full Text] [Related]  

  • 19. GLRX inhibition enhances the effects of geftinib in EGFR-TKI-resistant NSCLC cells through FoxM1 signaling pathway.
    Wang L; Liu J; Liu J; Chen X; Chang M; Li J; Zhou J; Bai C; Song Y
    J Cancer Res Clin Oncol; 2019 Apr; 145(4):861-872. PubMed ID: 30661098
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The canonical TGF-β/Smad signalling pathway is involved in PD-L1-induced primary resistance to EGFR-TKIs in EGFR-mutant non-small-cell lung cancer.
    Zhang Y; Zeng Y; Liu T; Du W; Zhu J; Liu Z; Huang JA
    Respir Res; 2019 Jul; 20(1):164. PubMed ID: 31331328
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.